evolus™

Jeuveau™

Special Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; prospective product candidate; the timing of and our ability to obtain and maintain regulatory approvals; ability to commercialize our product candidate; our ability to acquire rights to other product candidates; research and development costs; timing and likelihood of success, plans and objectives of management for future operations; products and product candidates; the potential market acceptance, demand market size, adoption rate and and future results of our product candidate, are forward-looking statements.

These forward-looking statements involve substantial known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to obtain and maintain on a timely basis, or at all, regulatory approval of our product candidate; our reliance on our exclusive third-party manufacturer and supplier of our product candidate; the sufficiency of our cash resources and needs for additional financing; our ability to commercialize our product candidate; the size and growth of the potential markets for our product candidate and the ability to serve those markets; the rate and degree of market acceptance of our product candidate; our anticipated growth strategies; the anticipated trends and challenges in our business and the market in which we operate; our ability to establish and maintain development partnerships; our ability to attract or retain key personnel; our expectations regarding federal, state and foreign regulatory requirements; and regulatory developments in the United States and foreign countries and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our Annual Report on Form 10-K for the year ended December 31, 2017 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which are on file with the Securities and Exchange Commission, or SEC. All of our filings are available on the SEC's website at www.sec.gov. All written and verbal forward-looking statements attributable to our Company or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. We may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations.

Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

Further Information

Certain of the industry, statistical and market data in this presentation was obtained from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this presentation involves a number of assumptions and limitations. While we believe that the information from these industry publications, surveys and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, which could cause results to differ materially from those expressed in the estimates made by third parties and by us.

EVOLUS™ & Jeuveau™ are two of our trademarks that are used in this presentation. This presentation also includes trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this presentation appear without the ® and ™ symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Jeuveau™ (prabotulinumtoxinA-xvfs) also known by it's clinical name, DWP-450, which is referenced in this presentation, is an investigational product candidate that is being evaluated for the treatment of moderate to severe glabellar lines in adult patients and has not been approved by the U.S. Food and Drug Administration.

Our financial results are prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). This presentation includes non-GAAP financial measures. Our reconciliations of non-GAAP financial measures to GAAP financial measures are located at the end of this presentation. These non-GAAP financial measures should not be considered as an alternative to GAAP financial measures.

Launching a new chapter in aesthetics

New Product Candidate Jeuveau™

- Expected to be the first known 900kDa molecule in the U.S. since Botox launched
- EU / Canada Phase III head-to-head data versus market leader met primary endpoint
- PDUFA action date of Feb. 2, 2019 with an anticipated Spring 2019 launch

Jeuveau™ expected to be the anchor product for building an aesthetic portfolio

High-Impact, Disruptive Launch

- High-touch pre-launch activities escalating into 2019
- Connected experience drives frictionless commerce

Only Known Neurotoxin Dedicated to Aesthetics

- Pricing flexibility unconstrained by reimbursement
- Greater focus on physicians and practice development

evolus™

Jeuveau™ is an investigational product candidate that is being evaluated for the treatment of moderate to severe glabellar lines in adult patients and has not been approved by the U.S. Food and Drug Administration.

>2,100 Patients Studied Across Multiple Clinical Trials

U.S. Phase III: Jeuveau™ vs. Placebo

- Two identical Phase III safety and efficacy studies (EV-001 & EV-002)
- Multicenter, randomized, double-blind, placebo controlled, single dose, 150 days duration
- Placebo controlled, superiority design
- EV-001 n = 330
- EV-002 n = 324

EU / Canada Phase III: Jeuveau™ vs. Botox

- EU / Canada Phase III safety and efficacy (EVB-003)
- Multicenter, randomized, double-blind, placebo & active controlled, single dose, 150 days duration
- Active control, non-inferiority design
- n = 540

Jeuveau™ Safety Studies

- U.S. Phase II Long-Term Safety Study (EV-004 & EV-006)
- Multicenter, non-randomized, open label, multiple dose, 365 days duration
- EV-004 n = 352
- EV-006 n = 570

Deep industry knowledge and commercialization experience

Highly Experienced Management Team

David Moatazedi
President and CEO

Lauren Silvernail
CFO and EVP,
Corporate Development

Rui Avelar, MD
Chief Medical Officer
and Head of R&D

Michael Jafar
Chief Marketing Officer

Amy Fox
Vice President,
Human Resources

Jeff Plumer
Vice President, Legal

Kurt Knab
Vice President, Sales

Alex Sabad
Vice President, Operations


Differentiated
Marketing
Frictionless
Alternative

Jeuveau™: Frictionless Alternative

Creating a strongly desirable experience for customers and consumers

Extensive Industry Expertise

Phase 3 Head-to-Head Data



Simple, Personal and Connected



Consumer Loyalty



Key 2019 Catalysts

Expected Launch in Three Major Markets

1. PDUFA date of February 2, 2019
2. Expect U.S. commercial launch in Spring 2019
3. Anticipated Publications: U.S Trials in Q1’19, EU / Canada head-to-head trials in Q2’19
4. EU CHMP opinion expected in Q1’19; if positive opinion, approval expected by Q2’19
5. Expect Canada commercial launch in 1H’19

evolus™

THANK YOU